12 terminated. 12 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Terminated 12 |
| Phase 2 | 3 | Terminated 3 |
Follow Chronic Obstructive Pulmonary Disease: new trials by email Literature Review of Chronic Obstructive Pulmonary Disease trials Research Report on Chronic Obstructive Pulmonary Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects TQC3302 inhalation spray, TQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation, Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation+ TQC3302 inhalation spray - Chronic Obstructive Pulmonary Disease | Phase 1 | Terminated | Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. | 33 | 2025-11-25 | 2026-08-27 |
| A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease GDC-6988 - Non-cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease | Phase 1 | Terminated | Genentech, Inc. | 17 | 2024-11-18 | 2026-10-20 |
| Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease ARO-MUC5AC, Placebo - Asthma, Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Terminated | Arrowhead Pharmaceuticals | 78 | 2022-06-27 | 2026-09-14 |
| Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers. Abediterol (2.4 μg), Abediterol (4.8 μg), Abediterol (2.5 μg) - Chronic Obstructive Pulmonary Disease | Phase 1 | Terminated | AstraZeneca | 25 | 2020-01-28 | 2020-04-21 |
| Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide - Chronic Obstructive Pulmonary Disease, Asthma | Phase 1 | Terminated | Chiesi Farmaceutici S.p.A. | 19 | 2019-01-14 | 2022-05-06 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD CHF6297 (Part 1 - SAD), Placebo (Part 1 - SAD), CHF6297 (Part 2 - MAD) - Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Terminated | Chiesi Farmaceutici S.p.A. | 118 | 2016-01-22 | 2020-04-17 |
| An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients TV48108, Placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 61 | 2015-04-01 | 2021-11-09 |
| Safety, Tolerability and Preliminary Efficacy of Adipose Derive Stem Cells for Patients With COPD ADSCs administration - Chronic Obstructive Pulmonary Disease | Phase 1 | Terminated | Arkansas Heart Hospital | 9 | 2013-10-10 | 2020-01-27 |
| Functional Applications of Hyperpolarized 129Xe MRI Hyperpolarized 129Xe gas - Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Terminated | Brigham and Women's Hospital | 1 | 2013-01-01 | 2018-04-17 |
| A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects GS-5737 - Cystic Fibrosis, Chronic Obstructive Pulmonary Disease | Phase 1 | Terminated | Gilead Sciences | 7 | 2012-10-01 | 2014-03-20 |
| A Study to Assess Safety, Tolerability and Pharmacokinetics of of AZD6553 in Healthy Volunteers and Patients With Chronic Obstructive Pulmonary Disease (COPD) AZD6553, Placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Terminated | AstraZeneca | 109 | 2010-02-01 | 2010-09-24 |
| Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7) SCH 527123, Placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 18 | 2010-02-01 | 2015-03-26 |
Pulmonary Disease, Chronic Obstructive (12) · Asthma (2) · Bronchiolitis Obliterans Syndrome (1) · Cystic Fibrosis (1) · Respiration Disorders (1)
Chronic Disease (12) · Disease Attributes (12) · Lung Diseases (12) · Lung Diseases, Obstructive (12) · Pathologic Processes (12) · Pathological Conditions, Signs and Symptoms (12) · Respiratory Tract Diseases (12) · Bronchial Diseases (3) · Immune System Diseases (3) · Hypersensitivity (2) · Hypersensitivity, Immediate (2) · Respiratory Hypersensitivity (2) · Bronchiolitis (1) · Bronchiolitis Obliterans (1) · Bronchitis (1)
2-hydroxy-N,N-dimethyl-3-(2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-enylamino)benzamide (1) · 5-(2-((6-(2,2-difluoro-2-phenylethoxy)hexyl)amino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one (1) · Inhalation (1) · Tiotropium Bromide (1)
AstraZeneca (2) · Chiesi Farmaceutici S.p.A. (2) · Arkansas Heart Hospital (1) · Arrowhead Pharmaceuticals (1) · Brigham and Women's Hospital (1) · Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. (1) · Genentech, Inc. (1) · Gilead Sciences (1) · Merck Sharp & Dohme LLC (1) · Teva Branded Pharmaceutical Products R&D, Inc. (1)
United States (5) · United Kingdom (4) · Australia (2) · New Zealand (2) · China (1) · Germany (1) · Poland (1) · South Korea (1) · Spain (1) · Thailand (1)
Dave Singh, MD (1) · Jason Holder, MD (1) · Joanna Marks-Konczalik (1) · Mark Bresnik, M.D. (1) · Samuel Patz, PhD (1) · Stuart Mair, MD (1) · T G K Mant, FRCP (UK) FFPM (1)
2008 (1), 2009 (1), 2015 (1), 2017 (1), R01HL096471 (1)